A Study to Assess the Safety and Tolerability PK and Efficacy of KPG-818 in Mild to Moderate SLE Patients

  • STATUS
    Recruiting
  • End date
    Dec 1, 2022
  • participants needed
    64
  • sponsor
    Kangpu Biopharmaceuticals, Ltd.
Updated on 17 June 2021

Summary

SYNOPSIS

Study Title

A phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability, pharmacokinetics and preliminary efficacy of KPG-818 in patients with mild to moderate systemic lupus erythematosus

Brief Title:

Phase 1b/2a study to evaluate safety and efficacy of KPG-818 in SLE

Objectives

Phase 1b

The primary objectives of the study are:

  • to assess the safety and tolerability of multiple oral doses of KPG-818 in patients with mild to moderate systemic lupus erythematosus (SLE).
  • to characterize the multiple oral dose pharmacokinetics (PK) of KPG-818 and its metabolite, KPG-818H, at Week 2.

The exploratory objectives of the study are:

to evaluate the change from baseline in potential biomarkers (Aiolos, Ikaros, CRBN proteins) of KPG-818 in peripheral blood mononuclear cells and CD19+ B Cell at Week 2.

Phase 2a

The primary objective of the study is:

to evaluate the preliminary efficacy of KPG-818 on disease activity by the change from baseline in Safety of Estrogens in Lupus National Assessment (SELENA)- Systemic Lupus Erythematosus Disease Activity Index (SLEDAI, SELENA- SLEDAI) at Week 12.

The secondary objectives of the study are:

  • to evaluate the efficacy of KPG-818 by the change from baseline in Physician Global Assessment (PGA) at Week 12.
  • to evaluate the effects of KPG-818 by the change from baseline in cutaneous manifestations by the change in Cutaneous Lupus erythematosus disease Area and Severity Index (CLASI) activity score of SLE Week 12.
  • to assess the safety and tolerability of multiple oral doses of KPG-818 at Week 12.
  • to assess the safety and tolerability of multiple oral doses of KPG-818 at Week 16.
  • to characterize the multiple oral dose pharmacokinetics (PK) of KPG-818 and its metabolite, KPG-818H, at Week 12.

The exploratory objectives of the study are:

  • to evaluate the change from baseline in potential biomarkers (Aiolos, Ikaros, CRBN proteins) of KPG-818 in peripheral blood mononuclear cells and CD19+ B Cell at Week 12.
  • to evaluate pharmacodynamics of KPG-818 at Week 12.
  • to select dosing regimens for a Phase 2b/phase 3 study.

Details
Condition SLE; Drug, SLE; Drug
Treatment Placebo, 0.15mg KPG-818 dose, 0.6mg KPG-818 dose, 2mg KPG-818 dose
Clinical Study IdentifierNCT04643067
SponsorKangpu Biopharmaceuticals, Ltd.
Last Modified on17 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female of 18 years of age or older at the time of signing the informed consent form (ICF)
Body mass index (BMI) between 18 and 40 kg/m2
Able and willing to adhere to the visit schedule and other protocol requirements
Fulfils the 2019 EULAR/ACR classification criteria for SLE (See Appendix 1)
Fulfils below requirements
For the Phase 1b part of the study, patients with or without active SLE may be enrolled if, in the opinion of the Investigator, the disease activity is stable and there will be no need for change or increase in SLE therapy anticipated for the study duration. If patients are on stable standard care of SLE treatment, this should comply with inclusion criteria No. 11
For the Phase 2a part of the study, patients must have a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score of 6 points at Screening visit with a SLEDAI-2K clinical score 4 points at Baseline visit. The "clinical" score is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or blood laboratory results including immunologic measures. Neurologic descriptors of the SLEDAI-2K are not counted towards the SLEDAI study entry criteria. In addition, the patient must be on stable standard care of SLE treatment with at least one of the followings: oral corticosteroids (OCS), anti-malarial, or immunosuppressant (see inclusion criteria No. 11 for allowed medications and doses)
Documented history or presence at Screening of positive autoantibodies associated with SLE, which must include at least 1 of the following
Positive antinuclear antibody (ANA) test with a titer of 1:80 or greater
Anti-dsDNA antibodies elevated to above normal
Anti-Smith antibody elevated to above normal
Women of childbearing potential (WOCBP) must
Have 2 negative serum pregnancy tests as verified by the Investigator prior to starting study therapy, 1 at Screening and again within 3 days before taking the first dose of KPG-818, then have a negative urine pregnancy test at Baseline before dosing. WOCBP must agree to ongoing pregnancy testing during the course of the study and after end of study treatment. This applies even if the patient practices true abstinence from heterosexual contact
Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use 2 forms of reliable contraception simultaneously. One must be a highly effective method and 1 additional effective (barrier) method (see Appendix 5 for more details), and both must be practiced without interruption, at least 28 days before starting investigational medicinal product (IMP), during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy
Male patients must: Practice true abstinence or agree to use a barrier contraception (male latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]) during sexual contact with WOCBP while participating in the study, and for at least 90 days following IMP discontinuation, even if he has undergone a successful vasectomy. Male patients must agree not to donate semen or sperm during the treatment period and for at least 90 days following the discontinuation of KPG-818
Female patients who are postmenopausal must demonstrate a follicle stimulating hormone (FSH) blood levels of equal or greater than 40 mIU/mL at the Screening visit. Women aged > 60 years old whose FSH values are not equal or greater than 40 mIU/mL may be included at the discretion of the Investigator and in consultation with the Sponsor (see Appendix 5 for more details)
All patients must
Understand that KPG-818 could have potential teratogenic risk
Agree not to share KPG-818 with another person
Be counseled about pregnancy precautions and risks of fetal exposure as described in the Pregnancy Prevention Plan
In Phase 2a part of the study, the patient must be on stable standard care of SLE treatment with at least one of the followings: oral corticosteroid, anti-malarial, or
immunosuppressant
If taking OCS, must be on-treatment for 4 weeks before the Screening visit, and maintained on a stable dose of 20 mg/day of prednisone or equivalent for at least 4 weeks before the Baseline visit
If taking an anti-malarial agent (hydroxychloroquine, chloroquine, or quinacrine), must be on-treatment for 8 weeks before the Screening visit and be on a stable dose for 4 weeks before the Screening visit. Anti-malarials at the following doses are allowed
Hydroxychloroquine ( 400 mg/day)
Chloroquine ( 500 mg/day)
Quinacrine ( 200 mg/day)
If taking allowed immunosuppressants, must be on-treatment for 8 weeks prior to the Screening visit and be on a stable dose for 4 weeks before the Screening visit. Only 1 of the immunosuppressants below is allowed at the indicated doses
Micophenolate mofetil ( 2 g/day) or mycophenolic acid ( 1.44 g/day)
Azathioprine ( 200 mg/day)
Methotrexate ( 20 mg/week)
Leflunomide ( 20 mg/day)
If taking NSAIDs or other regularly administered analgesics, these will be allowed if treatment started 4 weeks before the Baseline visit and dosing has not been changed within the last 2 weeks before the Baseline visit
If immunosuppressants, anti-malarial, or OCS is discontinued, the last dose must be more than 4 weeks prior to Screening visit
Patients must agree not to donate blood (or any component of blood) from 3 months before Screening until 3 months after the last dose of KPG-818
Patients must be willing to comply with precautions to reduce the risk of COVID-19 infection in accordance with recommendations from the applicable medical associations and the Investigator for the duration of the study, and to undergo COVID-19 polymerase chain reaction (PCR) test as required based on the Investigator judgment and/or local requirements

Exclusion Criteria

Must be off prohibited medications for a pre-specified period of time (see Appendix 6 for more details)
Any of the following noted at Screening (within 6 weeks before Week 1 [Day 1] in Phase 1b, within 4 weeks before Week 1 [Day 1] in Phase 2a)
Aspartate aminotransferase (AST) > 2.0 ULN
Alanine aminotransferase (ALT) > 2.0 ULN
Total bilirubin > 1.5 ULN (unless due to Gilbert's syndrome)
Serum creatinine > 2.5 mg/dL (or > 221 mol/L)
Neutrophil count < 1500/L (or < 1.5 109/L) (< 1000/L [or < 1.0 109/L] if the neutropenia is related to SLE)
Platelet count < 50 000/L (or < 50 109/L) (< 25 000/L [or < 25 109/L] if the thrombocytopenia is related to SLE)
Hemoglobin < 8 g/dL (or < 80 g/L) (< 7 g/dL [or <70 g/L] if related to SLE)
Have an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73 m2 (CKD-EPI formula) at Screening
Have a spot urine protein to creatinine ratio (sUPCR) > 2000 mg/g (226 mg/mmol, as an estimate of approximate proteinuria > 2 g/day) at Screening
Active and/or unstable neuropsychiatric SLE (e.g., neuropsychiatric SLE including seizures, psychosis, acute confusional state, cerebrovascular accident, aseptic meningitis, or polyneuropathy)
Positive serology test for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV-1 and HIV-2) at Screening. In cases of a positive screening test, patient may be enrolled if a confirmatory test is negative (see Appendix 3 for details). Exception: patient who test positive for HCV antibodies may be enrolled if confirmed with cured HCV infection and documented completion of treatment more than 3 months before screening and HCV must not be detectable at screening
Active or history of severe systemic bacterial, viral, fungal, mycobacterial, or parasitic infections (requires hospitalizations or IV antibiotics) within 6 months prior to Screening
Any current or recent (within 4 weeks of Screening) signs or symptoms of infection, except for fungal infections of the nail beds, oral or vaginal candidiasis that has resolved, or minor infections (e.g., common cold, viral gastroenteritis, urinary tract infection) that have in the Investigator's judgment, completely resolved prior to the Baseline visit
Any severe, recurrent, disseminated viral infections, particularly herpes viruses such as HSV-1, HSV-2, VZV, CMV (e.g., herpes encephalitis, ophthalmic herpes, disseminated zoster, CMV colitis) per Investigator's judgment. Recurrent is defined as 2 or more episodes in the past 2 years and/or with an episode within 3 months of Screening
Known history of congenital or acquired immunodeficiency, splenectomy, or any underlying condition that predisposes the patient to infection
Active tuberculosis (TB) or a history of incompletely treated TB, or a positive, QuantiFERON-TB Gold test. If a patient's initial TB test result is indeterminate, the test can be repeated once. If the test result is again indeterminate (or positive), the patient will be excluded from the study. An exception for positive or indeterminate results may be made for patients who have documentation of having completed appropriate standard treatment for latent TB before screening and do not have other risk factors, radiologic findings, or physical evidence supporting latent or active TB
Malignancy or history of malignancy, except for
Treated (e.g., cured) basal cell or squamous cell in situ skin carcinomas
Cervical cancer in situ that has been successfully treated
History of antiphospholipid syndrome with thromboembolic event within 12 months of screening or not on an adequate anticoagulation regimen. However, presence of antiphospholipid antibodies alone (without a history of thromboembolic event) is not exclusionary
Other non-SLE driven inflammatory joint or skin disease, mixed connective tissue disease, scleroderma, and/or overlap syndromes. An exception may be allowed for rheumatoid arthritis overlapping with SLE (i.e., RUPUS) with no erosive joint disease after a discussion with the medical monitor. Patients with SLE and secondary Sjogren syndrome are not exclusionary
Clinically significant or unstable or uncontrolled acute or chronic disease not related to SLE that in the Investigator's opinion would preclude patient participation
Concomitant condition (such as asthma) that required systemic corticosteroid use within 1 year before Screening. Use of inhaled corticosteroid is not exclusionary
History of alcohol or drug abuse within 1 year before screening based on the Investigator's judgement
Have a positive urine drug test at screening (see Appendix 3) except if the patient has a valid prescription for an allowed concomitant medication or substance abuse/dependence has been ruled out in the Investigator's judgment
History of major surgery within 12 weeks prior to Screening or any planned major surgery during the study
Clinically significant ECG abnormalities or have a corrected QT (QTc) interval value > 480 ms at Screening, in the Investigator's opinion would preclude patient participation
Pregnant or breastfeeding female
Signs or symptoms that in the opinion of the Investigator, may be suggestive of COVID-19 infection. The patient may be allowed to enter the study if a COVID-19 PCR test performed during the Screening results in a negative outcome
Known allergic reaction to any of the ingredients for study drug or placebo
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note